Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)

NCT06060652 is registered in ClinicalTrials.gov with Centro di Riferimento Oncologico - Aviano as lead sponsor.

NCT NCT06060652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06060652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)
Lead sponsor
Centro di Riferimento Oncologico - Aviano
Phase
Observational
Overall status
Unknown status
Start date
May 11, 2023
Completion date
May 11, 2026
Enrollment
104 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic prostate cancer